Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT03288168 | Children's and Adolescents' Medulloblastoma Molecular Subgroups in China(CNOG-MB001) | unknown | — | 200 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT03044769 | Congenital Lung Anomalies (CLA) Swiss Database(CLADatabase) | unknown | — | 100 | University Hospital, GenevaOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma(PEPI) | completed | Phase 2 | 13 | Baylor College of MedicineOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02786719 | High-Risk Neuroblastoma Chemotherapy Without G-CSF(SPRING) | completed | N/A | 13 | Baylor College of MedicineOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02100930 | Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | completed | N/A | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03545542 | Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma | unknown | N/A | 20 | Medical University of GrazOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | terminated | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00503893 | Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies | unknown | — | 295 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03968471 | Chemotherapy-induced Necrosis in Ewing Sarcoma | completed | — | 474 | Istituto Ortopedico RizzoliOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | terminated | Phase 2 | 3 | Nicklaus Children's Hospital f/k/a Miami Children's HospitalOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01991652 | Collaborative Wilms Tumour Africa Project | unknown | — | 400 | Amsterdam UMC, location VUmcOTHER | 3 | Jan 3, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT00339898 | Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma | completed | — | 414 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00410670 | Chordoma Family Study | completed | — | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00758108 | Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions | completed | — | 197 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 12, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes | terminated | — | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00001564 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT01114555 | Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma | completed | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | terminated | — | 150 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | terminated | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01492673 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 29, 2019 | clinicaltrials |
| NCT00987636 | Study in Localized and Disseminated Ewing Sarcoma(EWING2008) | completed | Phase 3 | 907 | University Hospital MuensterOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01334515 | Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | completed | Phase 2 | 52 | Children's Oncology GroupNETWORK | 2 | Oct 21, 2019 | clinicaltrials |
| NCT01183416 | High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01418495 | Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma | completed | — | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04065204 | Metabolomic Analysis of Body Fluid of Medulloblastoma in Children | unknown | — | 100 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT01183429 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01183897 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02693171 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | terminated | — | 13 | United TherapeuticsINDUSTRY | 1 | Aug 5, 2019 | clinicaltrials |
| NCT04042597 | Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma(CSSG-03) | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT00539500 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | terminated | Phase 2 / Phase 3 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00436852 | ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 2 | 92 | Children's Oncology GroupNETWORK | 2 | Jul 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2020source: clinicaltrials